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ABSTRACT  
   
Patients with malignant brain tumors have a median survival of approximately 15 months 
following diagnosis, regardless of currently available treatments which include surgery followed 
by radiation and chemotherapy. Improvement in the survival of brain cancer patients requires the 
design of new therapeutic modalities that take advantage of common phenotypes. One such 
phenotype is the metabolic dysregulation that is a hallmark of cancer cells. It has therefore been 
postulated that one approach to treating brain tumors may be by metabolic alteration such as that 
which occurs through the use of the ketogenic diet (KD). The KD is high-fat, low-carbohydrate 
diet that induces ketosis and has been utilized for the non-pharmacologic treatment of refractory 
epilepsy. It has been shown that this metabolic therapy enhances survival and potentiates 
standard therapy in mouse models of malignant gliomas, yet the anti-tumor mechanisms are not 
fully understood.  
The current study reports that KetoCal® (KC; 4:1 fat:protein/carbohydrates), fed ad 
libitum, alters hypoxia, angiogenic, and inflammatory pathways in a mouse model of glioma. 
Tumors from animals maintained on KC showed reduced expression of the hypoxia marker 
carbonic anhydrase 9 (CA IX), a reduction in hypoxia inducible factor 1-alpha (HIF-1α) and 
decreased activation of nuclear factor kappa B (NF-κB). Animals maintained on KC also showed 
a reduction in expression of vascular endothelial growth factor receptor 2 (VEGFR2) and 
decreased microvasculature in their tumors. Further, peritumoral edema was significantly reduced 
in animals fed the KC and protein analysis showed significantly altered expression of the tight 
junction protein zona occludens-1 (ZO-1) and the water channeling protein aquaporin-4 (AQP4), 
both of which have been implicated in malignant processes in glioma, including the formation of 
peritumoral edema in patients. Taken together the data suggests that KC alters multiple 
processes involved in malignant progression of gliomas. A greater understanding of the effects of 
the ketogenic diet as an adjuvant therapy will allow for a more rational approach to its clinical use. 
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INTRODUCTION AND BACKGROUND 
 
Brain Tumors 
 
Glioblastoma multiforme (GBM), the most aggressive type of brain tumor, represents one of the 
greatest challenges in the management of cancer patients worldwide. Despite aggressive surgery 
followed by radiation and chemotherapy, patients with newly diagnosed GBM have an average life 
expectancy of 12-18 months and less than 10% survive 5 years 
1, 2
. Brain tumors are highly infiltrative, 
and surgery rarely removes all tumor cells, particularly from eloquent areas of the brain. Further, while 
radiation and chemotherapy can kill most of the remaining tumor cells, those that survive typically regrow. 
Thus, these tumors often recur within 2 years of their original diagnosis and in the same general area as 
the primary tumor. The proximity of the recurrent tumor to the primary tumor often precludes the use of 
additional standard radiation therapy because of toxicity concerns 
3
. Once a GBM recurs following 
chemotherapy with temozolomide (TMZ), there are few additional chemotherapeutic agents with 
demonstrated efficacy for these tumors. The identification of new therapeutic targets for malignant 
gliomas has focused on molecular targets, often those found through global analyses done by The 
Cancer Genome Atlas consortium 
4
 and other groups 
5-8
. This work demonstrated that there are 
approximately four molecular subtypes of GBMs based on genetic aberrations, gene expression profiling 
and protein expression. One goal of these studies is the identification of therapeutic targets and a better 
understanding of how to determine the patients most likely to benefit from a specific targeted agent 
9
. 
However, solid tumors are heterogeneous, and these targets are typically not found on all cells in a 
tumor. The failure to successfully manage primary GBM and its recurrence remains a major challenge, 
and advances in survival and quality of life rely on new therapeutic approaches. 
 
Tumor Metabolism 
 
Cancer cells must meet the demands of rapid proliferation, thus cellular energy metabolism is one 
of the main processes affected during the transition from normal to cancer cells. Otto Warburg first 
described this shift in what we now call aerobic glycolysis or the “Warburg Effect” in 1924 
10, 11
. The 
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Warburg Effect describes the tumor cell’s use of glycolysis to provide energy and biomolecules regardless 
of the availability of oxygen. Under adequate oxygenation, normal cells rely on mitochondrial oxidative 
phosphorylation to generate ATP and switch to the less favorable anaerobic pathway of glycolysis when 
exposed to hypoxia. However, many types of cancer cells survive and proliferate by generating ATP via 
glycolysis rather than oxidative phosphorylation even when oxygenated; a process that occurs very early 
in tumorigenesis, prior to hypoxia 
12
. We now know that cancer metabolism is much more complex than 
just a higher rate of glycolysis. Mitochondrial biogenesis is also altered, and the cancer cell’s fate 
becomes reliant on the balance between the availability of energy, sufficient macromolecular synthesis for 
increased growth, and the modulation of reactive oxygen species (ROS)
13, 14
. 
Since Warburg’s discovery, metabolism has been of interest in the cancer field, but it often 
seemed overshadowed by discoveries of oncogenes, tumor suppressor genes, growth factor pathways, 
molecular subtypes of cancers, etc. There is a resurgence of interest in metabolism as a central theme in 
cancer, and we continue to find that metabolic pathways intersect and often regulate key components of 
tumor initiation, progression and therapy response 
15, 16
. Many pathways long known to be associated with 
tumor cell growth, escape from apoptosis, aggressive blood vessel formation (angiogenesis) and therapy 
resistance have now been linked to cellular metabolism 
17
. For example, p53 is a tumor suppressor 
encoded by TP53 which is frequently mutated in cancer. P53 promotes a variety of cellular responses to 
hypoxia, DNA damage and oncogene activation; however, recently it has been found to regulate 
glycolysis and assist in maintaining mitochondrial integrity 
18
. The overactivation of the stress responsive 
PI3K/AKT signaling pathway, typical in many cancers, has also been closely linked to metabolism and 
under low glucose conditions results in rapid tumor cell death 
17, 19, 20
. Hypoxia, a common occurrence in 
the tumor microenvironment, induces hypoxia inducible factor 1 (HIF-1), which regulates the uptake of 
glucose and the expression of a number of genes involved in glycolysis and energy metabolism 
21
. Myc, 
an oncogene long known to be involved in malignant cell transformation has also been shown to play a 
role in metabolic regulation, particularly in response to changes in the tumor microenvironment 
22
. These 
connections, and others, suggest that targeting metabolic changes can and should be considered in the 
context of other, more classic therapeutic targets.  
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The Ketogenic Diet 
 
The ketogenic diet (KD) is a medically regimented, high-fat low protein/carbohydrate diet used to 
treat refractory pediatric epilepsy 
23, 24
. It simulates fasting, thus increasing ketones and decreasing 
glucose in the blood, leading to high rates of fatty acid oxidation and an increase in the production of 
acetyl-CoA. When the amount of acetyl-CoA exceeds the capacity of the tricarboxylic acid cycle to utilize 
it, there is an increase in the production of the ketone bodies β hydroxybutyrate (βHB), acetoacetate 
(ACA) and acetone which can be used as an energy source in the brain 
25-28
. While the mechanisms are 
not fully understood, the neuroprotective effects of a KD on the brain have led to interest in using it for the 
treatment of a host of neurological disorders including Alzheimer’s disease, traumatic brain injury and 
amyotrophic lateral sclerosis 
29, 30
. 
It has been postulated that the KD may be useful as a therapeutic strategy in exploiting tumor 
metabolism and the Warburg Effect. Unlike normal brain cells, many tumor cells cannot utilize ketones 
effectively due to their various genetic and mitochondrial defects, and must rely on glucose as their 
primary energy source 
14, 31-36
. In addition, evidence suggests that ketone bodies may also be directly 
toxic to some human tumor cells 
37-39
. So by reducing the glucose availability to cancer cells and providing 
ketones as an alternative energy source for normal cells, the KD may offer an approach to targeting the 
Warburg Effect in highly glycolytic tumors, such as malignant gliomas. However, as we have learned 
primarily from the epilepsy literature, the action of the KD is more complex and its anti-tumor actions are 
likely to extend beyond the effects of reduced blood glucose. For example, the KD has been shown to 
reduce reactive oxygen species (ROS) production in the brain 
23, 40
. ROS are multi-faceted effector 
molecules involved in numerous cellular pathways, including those regulating autophagic/apoptotic 
responses to genotoxic stress, inflammation, hypoxia and nutrient deprivation. Cancer cells often have 
increased levels of ROS 
41
 and they have been implicated in angiogenesis induction and tumor growth 
through the regulation of the vascular endothelial growth factor (VEGF) pathway and HIF-1 
42
.  
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The KD in Preclinical Studies 
 
Recent studies have shown that the KD causes a reduction in blood glucose, an elevation of 
blood ketones and extends life in an immunocompetent mouse model of malignant glioma 
43, 44
. Results 
demonstrated that increasing blood ketones affects a number of tumor-related gene networks. This 
includes alteration in the expression of genes like cyclooxygenase-2 (COX-2) and others involved in the 
cellular response to oxidative stress in tumor tissue. There was also a concomitant reduction in reactive 
oxygen species (ROS) 
43
. A separate study using the same model found that the KD plus radiation 
therapy also reduced expression of COX-2 while reducing the production of ROS 
45
 in vivo. Additional 
changes in gene expression suggest that the KD may inhibit insulin-like growth factor (IGF-1), platelet-
derived growth factor (PDGF) and epidermal growth factor receptor (EGFR) signaling pathways 
39
 as has 
also been shown in various caloric restriction (CR) and restricted ketogenic diet (RKD) studies 
46-48
. 
The KD not only targets specific aspects of tumor biology as described above, but may also exert 
a global effect on the aberrant genetic landscape found in tumors. Results using cDNA Array technology 
demonstrated that overall gene expression in tumor from animals fed the KD was shifted more towards 
the gene expression found in non-tumor containing tissue from animals fed either the KD or standard diet 
43
 (Figure 1). While the mechanism(s) through which this global shift in gene expression as a result of the 
KD is not known, one hypothesis is that the KD may be altering the tumor epigenome. The epigenome 
describes the collection of abnormal, heritable changes in gene activity that are not caused by changes in 
the DNA sequence 
49
. These modifications include chromatin remodeling, histone modifications, DNA 
methylation, and microRNA pathways; all of which have now been linked to metabolism in many cancers, 
including brain tumors 
50, 51
. Epigenetic changes in cancer are now being looked at as potential 
therapeutic targets. New therapies such as histone deacetylase (HDAC) inhibitors are actively being 
tested for their ability to reverse the abnormal gene expression patterns inherent to the cancer epigenome 
and for their ability to enhance other anti-tumor therapies 
52, 53
. A recent study suggests that β-
hydroxybutyrate (βHB), the major ketone that is increased in the blood in animals and patients on the KD 
can alter the epigenetic landscape in mammalian cells by inhibiting HDAC 
54
. Another study showed that 
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the KD reversed the major epigenetic modifications found in the brains of epileptic rats 
55
. While the effect 
of the KD on tumor epigenetics has yet to be studied directly, evidence warrants further exploration. 
 
 
Figure 1: cDNA Microarray Data 
43
. Eight microarrays were analyzed by 2-way ANOVA for interaction effects, using 
standard Bonferonni multiple testing correction. There were strong interactions between ketogenic diet and normal 
diet in non-tumor classes, especially in context of standard diet non-tumor. The trend is that many expression profiles 
in tumor mice on a ketogenic diet seem to trend back to a profile seen with mice living on a standard diet having no 
tumor.  
 
KD as an Adjuvant Therapy 
 
While the studies described above show that the KD and/or CR provides various anti-tumor 
benefits on their own, evidence suggests that they may also enhance other therapies for brain tumors by 
either protecting normal tissue, working in synergy with other treatments, or both. Gene expression 
changes in the tumors from animals fed the KD were not the same as those in the non-tumor containing 
contralateral side of the brain 
39, 43
. This allows for the hypothesis that the neuro-protective activity of 
blood ketones may also function to reduce the deleterious side effect of cranial radiation on normal brain. 
A recent publication showed that fasting, which elevates blood ketones, not only sensitizes many types of 
cancer cells to standard therapies but may promote the protection of normal tissue from the toxicity 
associated with radiation and chemotherapy 
56
. 
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The KD as an adjuvant enhanced the anti-tumor effects of both chemotherapy and radiation. KD 
greatly enhanced survival in a mouse model of glioma when combined with TMZ when compared to 
either treatment alone 
57
. In addition, a separate study showed that 9 out of 11 animals maintained on the 
KD and treated with radiation had complete and sustained remission of their implanted tumors, even after 
being switched back to a standard rodent diet 
44
  (Figure 2). Another recent study found that combining 
the KD with radiation and chemotherapy resulted in decreased tumor growth rate and increased survival 
in a lung cancer xenograft model 
58
. Studies also show that CR and fasting may act in synergy with other 
anti-cancer therapeutics 
56, 59-62
.  
 
 
Figure 2: Kaplan-Meier Survival Analysis of Tumor-Bearing Mice 
44
. Kaplan-Meier plot of survival in KC versus 
SD (left), radiation versus KC plus radiation (right). Animals on KC survived significantly longer when treated with KC 
alone (p,0.005), or when combined with radiation (p,0.0001). Results are a combination of (left) 4 separate 
experiments and (right) 2 separate experiments. 
 
It has been suggested that the KD and/or caloric restriction may be more effective in combination 
with other agents targeting metabolism and specifically glucose. It has been shown that a KD given in 
combination with the glycolysis inhibitor, 2-deoxy-D-glucose (2DG), reduced the growth of a mouse CT-
2A astrocytoma to a greater extent than either therapy administered alone 
63
. Metformin, a therapy for 
diabetes mellitus, and the analog phenformin are becoming a focus in the cancer metabolism research 
community due to their antitumor activity in a variety of in vitro and in vivo cancer models, including brain 
tumors 
64
; however they have not been investigated in combination with CR or the KD. Hyperbaric oxygen 
is another experimental anti-cancer therapy that works by reversing tumor hypoxia, which can contribute 
to a tumor’s dependence on glycolysis 
65
 and it has recently been demonstrated that the KD showed a 
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synergistic effect when used with hyperbaric oxygen therapy, prolonging survival in a mouse model of 
metastatic cancer over either therapy alone 
66
. 
 
The Ketogenic Diet in Humans 
 
The first use of the KD for the treatment of human malignant brain tumors was in 1995 by 
Nebeling and colleagues 
67
. The patients in this study were two female children diagnosed with 
nonresectable advanced stage brain tumors (anaplastic astrocytoma stage IV and cerebellar astrocytoma 
stage III), both of which had undergone extensive radiation and chemotherapy. The goal of the study was 
to determine if dietary induced ketosis could decrease the availability of glucose to disrupt tumor 
metabolism while maintaining the nutritional status of the patients. Both children responded remarkably 
well to the KD, showing a reduction in glucose uptake and experiencing long-term tumor management. 
In 2010, researchers in Italy published a case report on 65-year-old female patient with 
multicentric glioblastoma multiforme (GBM) that was treated with a restricted calorie ketogenic diet (RKD) 
during standard radiation and chemotherapy. The patient followed the 4:1 (ratio of fats:carbohydrate plus 
protein) ketogenic diet restricted to 600kcal/day which resulted in reduced levels of blood glucose and 
elevated levels of urinary ketones. After two months on the diet, the patient's body weight was reduced by 
about 20%, however most importantly; no observable brain tumor was detected using either 
Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) or magnetic resonance imaging (MRI). 
Ten weeks after stopping the diet, the tumor recurred and CPT11 (Irinotecan) and bevacizumab 
chemotherapy was initiated 
68
. The patient succumbed to her disease less than 2 years after diagnosis. 
Nevertheless, this work demonstrated that the RKD could be tolerated in a brain tumor patient, at least for 
a short period of time, and it appeared to have some efficacy. In 2011, German researchers evaluated the 
restricted-calorie KD in 16 subjects with various types of advanced cancers who had exhausted all 
therapeutic options. This pilot trial showed that the KD did not cause any severe side effects or changes 
in cholesterol or blood lipids. Of the 16 subjects, 5 were able to complete the 3-month treatment period 
and none of these patients experienced further tumor progression while on the diet 
69
. Two of the 11 
remaining patients died early following the beginning of the trial, one was unable to tolerate the diet and 
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dropped out immediately, 2 patients dropped out for personal reasons, one was unable to continue the 
diet for more than a month and 3 had disease progression within less than 2 months of starting the diet 
and one dropped out to resume chemotherapy. On the whole, this pilot study demonstrated that the KD 
could be tolerated in some patients with advanced disease and it appeared to be beneficial in 5 of the 16 
subjects; however, the overall results were hard to interpret based on the variety and severity of disease 
in the enrolled patients.  
More recently, a number of prospective clinical trials have been initiated. A study in Germany is 
evaluating the efficacy of a calorie-restricted ketogenic diet and transient fasting during re-irradiation for 
patients with recurrent GBM (ClinicalTrials.gov, NCT01754350). Michigan State University is directing a 
similar trial evaluating a calorie-restricted KD for the management of recurrent GBM (NCT01535911). A 
third pilot study is evaluating the KD as adjunctive treatment in refractory/end-stage GBM 
(NCT01865162). In Pittsburgh, another study is evaluating the KD in a variety of advanced or metastatic 
cancers (NCT01716468). The goals for all of these studies are to obtain data on the safety, efficacy and 
tolerability of the KD as an adjunctive therapy for patients with GBM. 
The only study using the KD as an up-front, concurrent therapy has recently been approved and 
is now open for enrollment at St. Joseph’s Hospital and Medical Center and Barrow Neurological Institute 
in Phoenix, Arizona (NCT02046187). This trial for patients with primary GBM will evaluate the classic 4:1 
ketogenic diet therapy during radiation treatment and concurrent temozolomide followed by the modified 
Atkins Diet (1:1 fat:carbohydrate plus protein) during temozolomide treatment. 
While the KD holds promise as an anti-cancer therapy, clinical utilization is not without its 
challenges. More data is needed to define the optimum “therapeutic range” for blood glucose and ketone 
levels, and to determine if varying formulations of the KD would be more effective in different individuals. 
Further studies are also needed to determine the necessary duration and long term effects of the KD. A 
limited number of papers suggest that long term use of the UKD may in fact have deleterious effects 
including glucose intolerance in rats 
70-72
. However, it should be noted that the composition of the diet is 
critical, and the ongoing support of a registered dietician well versed in its use can reduce the likelihood of 
adverse effects in humans. In addition, the medical community must be educated on the therapeutic 
value of metabolic alteration as an adjuvant therapy, even if it results in a small amount of healthy weight 
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loss, since the current dogma is to avoid weight loss in patients undergoing chemotherapy for fear of 
increased fatigue and further decline in overall patient health. In fact, it has been suggested that a high fat 
diet may even reduce cachexic weight loss, a source of reduced overall health in cancer patients 
73
. As 
with any clinical decision, implementation of therapy must be guided by the assessment of the patient’s 
individual situation, which should include nutritional status. Quality of life is also a concern as this type of 
nutritional therapy requires discipline, motivation and careful guidance by a registered dietician 
experienced in implementing the KD. Compliance can be made more difficult by the use of steroids 
(prescribed for peritumoral edema) that often increase hunger and raise blood glucose levels. Despite 
these caveats, the existing preclinical data suggesting anti-tumor efficacy and a synergistic effect with 
standard therapies provides a strong impetus to conduct controlled clinical trials, particularly those that 
will shed light on the interactions between the KD and other therapies. 
 
Introduction to the Current Study 
 
The current study aims to further explore the anti-tumor mechanisms underlying the KD, 
specifically in the context of tumor hypoxia and angiogenesis. Mediators of the hypoxic response hypoxia 
including HIF-1α, NF-κB, and carbonic anhydrase IX (CA IX) were analyzed along with tumor vasculature 
and key mediators in the pro-angiogenic pathways, including VEGF and VEGFR2. In addition, the 
influence of the KD on peritumoral edema was explored and expression of tight junction proteins and 
aquaporins were analyzed.  
 
 
 
 
 
 
 
 
  10 
 
MATERIALS AND METHODS 
Ethics Statement 
 
This study was performed in strict accordance with the recommendations in the Guide for the 
Care and Use of Laboratory Animals of the National Institutes of Health. The protocol was approved by 
the Institutional Animal Care and Use Committee of St. Joseph’s Hospital and Medical Center (protocol 
number 334 (A3510-01)). All surgery was performed under ketamine/xylazine anesthesia, and every 
effort was made to minimize suffering.  
 
GL261 Mouse Model of Glioma 
 
Bioluminescent GL261-luc2 cells were derived as previously described 
44
 and were grown in 
Dulbecco’s modified eagles medium (DMEM) supplemented with 10% fetal calf serum (FCS) and 
100µg/ml Geneticin
®
 (G418, Invitrogen Corp, Carlsbad, CA) at 37
o
C with 5% CO2. Cells were harvested 
by trypsinization, washed and resuspended at a concentration of 1-2 x 10
7
 cells/ml in DMEM without FCS 
and implanted into 10 week old female C57BL/6–cBrd/cBrd/Cr (albino C57BL/6) mice (National Cancer 
Institute at Frederick Animal Production Program, Frederick, MD) at an average weight of 20 grams as 
described 
43, 44, 74
. Mice were housed in groups of 5 in the animal care facility of St. Joseph’s Hospital and 
Medical Center in rooms with controlled temperature and humidity under a 12-hour light-dark cycle 
according to the guidelines in the NIH Guide for Care and Use of Laboratory Animals.  
 
Treatment and Animal Monitoring 
 
Following surgery, animals were fed standard rodent chow for 3 days. Animals were then 
randomized to remain on standard rodent chow (SD) ad libitum or changed to KetoCal
®
 (KC; a generous 
gift from Nutricia North America, Gaithersburg, MD) ad libitum. KC was obtained directly from the 
manufacturer and is a nutritionally complete diet providing a 4:1 ratio of fats to carbohydrates plus protein 
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(72% fat, 15% protein, and 3% carbohydrate). A paste was prepared by mixing KC with water (2:1). 
Animals in each cage received a cubic inch of the paste each day which was sufficient to provide ad 
libitum feeding. 
Bioluminescence was analyzed to quantify tumor burden 43. Animals received a subcutaneous 
(s.c.) injection of 150μg luciferin (Perkin Elmer, Waltham, MA) per kg body weight 15 min prior to in vivo 
imaging using an IVIS
®
 Spectrum in vivo imaging system (Perkin Elmer). Tumor cells were detectable 3 
days post implantation (the first day they were imaged) and quantitation was done using the system’s 
Living Image
®
 4.3 software. Serum β-hydroxybutyrate levels were measured using a Precision Xtra
®
 
ketone monitoring system (Abbott Laboratories, Abbott Park, IL) and blood glucose levels were tested 
using Nova Max
®
 Plus blood glucose monitoring system (Nova Biomedical, Waltham, MA). Animals were 
weighed every 3-4 days and were euthanized upon occurrence of visible symptoms of impending death 
such as hunched posture, reduced mobility and weight loss 
44, 75
. 
 
In Vivo Imaging of Hypoxia 
 
At 21 days post-implantation, animals were administered HypoxiSense680™ (2 nmol/100 µl; a 
generous gift from Perkin Elmer, Inc.) by intraperitoneal injection and imaged 24 hours later using the 
IVIS
®
 Spectrum in vivo imaging system (675 ex/720 em; Perkin Elmer). Spectral unmixing was performed 
and quantitation was done using the system’s Living Image
®
 4.3 software. Each tumor bearing animal 
was imaged prior to injection of the probe to quantitate signal generated by tissue autofluorescence. 
Healthy, non-tumor bearing mice were injected with the probe and imaged 24 hours later to quantitate 
non-specific binding of the probe.  
 
Western Blotting 
 
On Day 21 post implantation, GL261-luc2 tumors and contralateral non-tumor containing brain 
tissue were homogenized in ice-cold RIPA buffer containing 150 mM sodium chloride, 1.0% NP-40, 0.5% 
sodium deoxycholate, 0.1% SDS and 50 mM Tris-Base (pH 8.0), protease inhibitor cocktail (Cell 
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Signaling Technology, Beverly, MA, USA) and PhosSTOP phosphate inhibitor tablets (Roche Applied 
Science, Indianapolis, IN, USA). Lysates were incubated on ice with agitation for 1.5 hours and then 
centrifuged at 12,000 RPM for 20 minutes. Protein concentrations were determined using the Pierce
®
 
BCA protein assay kit (Thermo Scientific, Rockford, IL, USA). Forty µg of total protein from each tissue 
sample was resolved by SDS-PAGE on 4-12% Bis-Tris gels (Life Technologies, Carlsbad, CA). Proteins 
were transferred to a nitrocellulose membrane for 1 hour in standard wet transfer buffer (25mM Tris, 
192mM glycine, 20% methanol) and blocked in 5% BSA in Tris-buffered saline with Tween-20 (TBST) for 
1 hour at room temperature. Blots were then incubated overnight at 4
o
C in primary antibodies against CA 
IX (1:1000; Proteintech, Chicago, IL), HIF-1α (1:500; Bioss, Woburn, MA), NF-κB (1:1000; Cell Signaling 
Technology), p-NF-κB (1:1000; Cell Signaling Technology), CD31 (1:5000; Novus Biologicals, Littleton, 
CO), VEGF (1:1000; Santa Cruz Biotechnology, Dallas, TX), VEGFR2 (1:5000; Novus Biologicals), ZO-1 
(1:200; Biorbyt, Cambridge, UK), Occludin (1:40; Biorbyt), Aquaporin-1 (1:1000; Abcam, Cambridge, UK) 
and Aquaporin-4 (1:1000; Abcam). After washing with TBST, blots were incubated in horseradish 
peroxidase (HRP) conjugated secondary antibody for 1 hour at room temperature and bands were 
visualized using the Novex
®
 ECL Chemiluminescent Substrate Reagent Kit (Life Technologies). Each 
membrane was stripped and reprobed for β-actin (1:6000; Abcam) as an internal loading control. 
Densitometry was used to determine the ratio of the target to β-actin (VisionWorks LS 7.1 software; UVP, 
Upland, CA).  
 
Immunohistochemistry  
 
Immunohistochemistry was performed on formalin fixed paraffin-embedded tissue sections. 
Following deparaffinization, antigen retrieval was done in sodium citrate buffer (10mM; pH 6.0) at 98
o
C for 
25 min and slides were then rinsed with cool dH2O. Sections were blocked with 1% bovine serum albumin 
in TBST for 1 hour at room temperature and incubated in Image-iT
®
 FX signal enhancer (Life 
Technologies, Carlsbad, CA) for 30 minutes at room temperature. The sections were then incubated in 
antibody against CD31 (1:2500, Novus Biologicals, Littleton, CO) primary antibody overnight at 4
o
C in a 
humidified chamber. Following washes in PBS, the sections were incubated with AlexaFluor
®
 488 goat 
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anti-rabbit IgG secondary antibody (1:1500, Life Technologies) for 1 hour at room temperature. To reduce 
lipofucsin induced autofluorescence, sections were incubated in 1 mM CuSO4 diluted in 50 nM 
ammonium acetate buffer (pH 5) for 1 hour at room temperature. Sections were then rinsed in dH2O and 
counterstained with VectaShield™ mounting media containing DAPI (Vector Laboratories, Burlingame, 
CA) prior to imaging.   
Immunostaining was imaged using a Zeiss LSM 710 microscope (Carl Zeiss International, 
Gottingen, Germany) and Zen software (Zeiss). Total CD31 staining was determined by averaging the 
pixel density in 5 random, 200x fields within the same tumor for each animal using Image J software (NIH, 
Bethesda, MD). The percentage of CD31 positive staining per analyzed area of the tumor was 
determined by normalized pixel threshold analysis. All values were normalized to the standard diet (SD) 
values and represented as a fold change.  
 
Gene Expression Analysis 
 
Tumor samples were dissected from non-tumor containing brain and total cellular RNA was isolated using 
the TRIzol
®
 LS Reagent (Life Technologies) and conditions specified by the manufacturer. RNA was 
further purified using an RNeasy
®
 Mini Kit (Qiagen, Valencia, CA), DNased using TURBO™ DNase 
(Ambion
®
, Life Technologies) and the quality was determined using an Agilent 2100 Bioanalyzer (Agilent 
Technologies, Palo Alto, CA). The Mouse Cancer RT² Profiler™ PCR Array was performed as a fee-for-
service by Qiagen. Fold changes in gene expression were calculated for tumors from animals fed a 
standard rodent diet versus KetoCal
®
. 
 
Measurement of Peritumoral Edema 
 
On Day 14 following tumor implantation, MR images were acquired on a Bruker Biospec 7.0T 
small animal MR scanner (Bruker Medizintechnik, Karlsruhe, Germany) with 72mm transmit coil and a 
surface receive coil. A multiple slice 2D T2-weighted RARE sequence was acquired as reference image 
(29 slices, 0.1mmx0.1mm, thickness 0.5 mm, TR= 4000 ms, effective TE = 60 ms, RARE factor=8) to 
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locate the slice with maximum size of tumor. Then a multi-echo T2 relaxometry sequence was used for T2 
mapping, in which a series of T2-weighted images were obtained at 28 different echo times, starting from 
10.57ms with 10.57ms increments, with in-plane resolution of 0.078mmx0.078mm, slice thickness 1.0 
mm, matrix size = 192x192, field of view = 15mmx15 mm, repetition time = 3000ms. The T2 map was 
derived by single-exponential fitting of the data. 
 
Statistical Methods 
 
Statistical analyses were performed using GraphPad Prism
®
 v 5.04 (GraphPad Software, San 
Diego, CA). All values are represented as the mean ± SD and significance was determined using the 
Student’s t test. P < 0.05 was considered statistically significant. 
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RESULTS 
 
Animals fed KC
 
show an increase β-hydroxybutyrate levels and a reduction in blood glucose 
 Animals fed KC had a statistically significant increase in blood βHB levels (Figure 3A) and 
decrease in blood glucose (Figure 3B) both 7 and 14 days post-implantation. Body weight remained 
stable throughout the course of the experiment (Figure 3C) and on day 21 post-implantation, all animals 
were euthanized to obtain tissue for ex vivo analysis. These findings are consistent with our previous 
results 
44
.  
 
 
Figure 3: Animal weight, βHB and Glucose Measurements. Animal ketone and glucose measurements show (A) 
higher βHB blood levels and (B) lower glucose in animals treated with KetoCal®. (C) Weight measurements were 
taken every 3 days. Graph shows animals weights normalized to the average starting weight of each group on day 
zero. (N=5; *p<0.05; **p<0.01; ***p<0.001). 
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KC reduces in vivo expression of the hypoxia marker, carbonic anhydrase IX 
The HypoxiSense 680™ fluorescent imaging agent detects expression of the hypoxia marker, 
carbonic anhydrase IX (CA IX) on the surface of tumor cells. Animals maintained on KC had a statistically 
significant reduction in HypoxiSense 680™ signal on Day 21 following implantation when compared to 
animals fed SD (Figures 4A and 4B). Tumor bearing animals were imaged prior to injection of the probe 
to quantitate signal generated by tissue autofluorescence (Figure 4B). Healthy, non-tumor bearing mice 
were injected with the probe and imaged 24 hours later to quantitate non-specific binding of the probe 
(Figure 4B). Bioluminescent tumor signal measured on the same day showed no significant difference in 
tumor signal between treatment groups (Figure 4C). 
 
 
Figure 4: In Vivo Imaging of Hypoxia. (A) 21 days following tumor implantationHypoxiSense 680™ was used to 
analyze hypoxia in vivo. (B) Spectral unmixing was performed to quantitate fluorescent signal from tumor bearing 
mice on each diet (N=5; *p<0.05). Each tumor-bearing animal was imaged just prior to injection to analyze tissue 
autofluorescence (“Before injection”; N=5; ***p<0.001) and healthy, non-tumor bearing mice were injected to analyze 
non-specific binding of the probe (“Normal Brain”; N=2; *p<0.05). (C) Tumor bioluminescence was measured on the 
same day and showed no significant difference in tumor size between SD and KC (N=5). 
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KC Reduces Expression of Proteins Involved with the Hypoxic Response  
Western blot analysis of tumor lysates was performed to examine the effects of KC on the 
expression of proteins important in the hypoxic response. Both CA IX and HIF-1α levels were significantly 
reduced in the tumors from animals fed KC when compared to those fed SD (Figure 5; N=6; *p<0.05; 
**p<0.01). Further, there was no difference in total NF-κB levels; however, there was a significant 
reduction in expression of the phosphorylated form, suggesting a reduction in the activation of NF-κB 
(Figure 5).  
 
 
Figure 5 Western Blot Analysis of CA IX, HIF-1α, phospho-NF-κB, and total NF-κB. (A) Western blot analysis of 
CAIX, HIF-1α, phospho-NF-κB and total NF-κB  protein expression was performed on whole lysates of tumor tissue 
and β-actin was used as a loading control. (B) Expression was quantified and represented as a fold change from SD 
(N=6; *p<0.05; **p<0.01).  
 
 
KC Reduces Tumor Microvasculature 
Western blot analysis was performed on whole lysate of GL261-luc2 tumors to examine the 
expression of the angiogenic marker, CD31 (Figure 6A). The results show a statistically significant 2-fold 
decrease in expression of CD31 in animals fed KC when compared to SD fed animals (Figure 6B). 
These results were confirmed using immunohistochemical staining of paraffin-embedded tissue 
sections. We showed a reduction in blood vessels in tumors from animals fed the KC when compared to 
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those fed SD (Figure 6C). Quantitation of staining demonstrated a statistically significant decrease in the 
percentage of CD31 positive areas within the tumors of animals fed KC (Figure 6D).  
 
 
Figure 6: CD31 Expression. (A) Western blot analysis of total CD31 protein expression was performed on the whole 
lysates of tumor tissue and β-actin was used as a loading control. (B) Expression was quantified and represented as 
a fold change from SD (N=5; *p<0.05). (C) Immunostaining for CD31 was performed on formalin-fixed, paraffin-
embedded tissue. Representative images from each tissue type are shown. (D) Quantification of CD31 staining was 
performed on 2 independent mouse brain tumors from each group. Data calculated as the average pixel density in 5 
random, 200x fields within the same tumor and represented as a fold change from SD (**p<0.01).  
 
 
KC alters expression of genes involved in angiogenesis and vascular modeling 
 Western blot analysis of tumor tissue was performed to examine the expression of the key 
regulators of tumor angiogenesis, VEGF and VEGFR2. Tumors from animals fed a KC showed no 
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difference in total VEGF expression but a significant reduction in VEGFR2 expression was found (Figure 
7A and 7B).  
 
 
Figure 7: Western Blot Analysis of VEGF and VEGFR2. (A) Western blot analysis of total VEGF and VEGFR2 
protein expression was performed on the whole lysates of tumor tissue and β-actin was used as a loading control. (B) 
Expression was quantified and represented as a fold change from SD (N= 6 for SD; N=5 for KC; *p<0.05). 
 
 
KC Reduces Expression of Genes Involved with Angiogenesis 
Tumor RNA was analyzed from animals fed KC and animals fed from SD using a mouse Cancer 
RT² Profiler™ PCR Array (Qiagen). The expression of a number of genes involved in various 
angiogenenic processes were found to be altered by KC (Figure 8). Of those genes, Vegfb, Plau, Timp1, 
Tek, and Itgb1 were expressed significantly lower in the tumors from animals fed a KC when compared to 
tumors from animals fed SD (Figure 8).  
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Figure 8: Gene Expression Analysis: The expression of genes involved in angiogenesis was analyzed. Data 
represented as the fold change difference in expression from SD tumors (N=3; *p<0.05; **p<0.01). 
 
 
KC Reduces Expression and Activation of MMP-2 
Western blot analysis was performed on tumor tissue to determine the expression levels of both 
the pro-form and the proteolytically processed activated form of MMP-2. Tumors from animals maintained 
on KC showed a significant reduction in both the pro- (72 KDa) and activated (65KDa) form of MMP-2 
(Figure 9A and 9B).  
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Figure 9: Western Blot Analysis of Pro- and Activated- MMP-2. (A) Western blot analysis of the pro- and 
activated- form of MMP-2 protein expression was performed on the whole lysates of tumor tissue and β-actin was 
used as a loading control. (B) Expression was quantified and represented as a fold change from SD (N=6 for SD; 
N=5 for KC; *p<0.05). 
 
KC Reduces Peritumoral Edema  
Peritumoral edema was measured by MRI on day 14 following implantation. Results show a 
statistically significant 2-fold decrease in peritumoral edema in animals fed KC when compared to those 
fed SD (Figure 10A). To demonstrate that the reduction in edema with the KC was not purely a function 
tumor size, bioluminescent tumor signals from the same day were analyzed and there was no statistical 
difference in signal between groups (Figure 10B). These results recapitulate previous results seen in a 
separate experiment (unpublished data) evaluating a higher fat formula of the ketogenic diet (6:1 fat to 
protein/carbohydrate; Bio-Serv F3666 KD, Frenchtown, NJ). The animals maintained on the 6:1 KD 
demonstrated elevated blood ketones, reduced blood glucose and a statistically significant reduction in 
peritumoral edema (N=6; *p<0.05; unpublished data).  
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Figure 10: Peritumoral Edema Measurements.  (A) 14 days following tumor implantation, edema was measured by 
MRI, showing a 2-fold decrease in peritumoral edema in animals fed KC when compared to those fed the SD (N=3; 
*=p<0.05). (B) Tumor bioluminescence was measured on the same day and showed no significant difference in tumor 
size between animals fed SD or KC.  
 
 
 
KC Influences Expression of ZO-1 and Aquaporin-4  
Western blot analysis of tumor tissue was performed to analyze the expression of proteins 
involved with peritumoral edema and glioma progression including the tight junction proteins, ZO-1 and 
occludin, as well as the water channeling proteins, AQPN-1, AQPN-4. Results show that tumors from 
animals fed a KC had a significant increase in the expression of ZO-1 but no difference in occludin 
expression (Figure 11A and 11B). Animals maintained on KC also showed a reduction in expression of 
AQPN-4 expression but not AQPN-1 (Figure 11A and 11B).  
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Figure 11: Western Blot Analysis of ZO-1, Occludin, Aquaporin-1 and Aquaporin-4. (A) Western blot analysis of 
zona occludens-1 (ZO-1), occludin, aquaporin-1 (AQP1) and aquaporin-4 (AQP4) protein expression was performed 
on the whole lysates of tumor tissue and samples were normalized to β-actin. (B) Quantification of expression was 
performed and data is represented as a fold change from SD (N=6 for SD; N=5 for KC; *p<0.05; **p<0.01). 
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DISCUSSION 
 
Early attempts to use metabolism as a therapeutic target often focused on caloric restriction (CR). 
In 1914, Payton Rous was the first to suggest that restricted food intake reduced tumor growth by 
reducing the tumor blood supply 
76
. More recently it has been suggested that CR reduces growth and 
angiogenic biomarker expression in prostate cancer and breast cancer 
77-80
. The combination of caloric 
restriction and the ketogenic diet (restricted ketogenic diet; RKD) has also been studied as a cancer 
therapy. The anti-proliferative and anti-angiogenic effects of CR and the RKD have been substantiated in 
a number of studies using experimental mouse and human brain tumor models 
14, 32, 46, 48, 81, 82
. Evidence 
also suggests that CR and the RKD alters inflammatory pathways, normalizes vasculature and may 
reduce peritumoral edema. In a mouse astrocytoma model, CR reduced expression of pro-inflammatory 
markers, cyclooxygenase-2 (COX-2), nuclear factor kappa B (NF-κB) and macrophage inflammatory 
protein (MIP-2) 
83
. Seyfried and colleagues recently showed that CR promoted vessel maturation by 
preventing vascular VEGF signaling in the CT-2A mouse astrocytoma model 
47
.  Further, a recent study in  
the U87 human glioma model showed that CR normalized a variety of factors involved in tumor vessel 
instability and leakiness, including VEGF, and showed a reduction of peritumoral edema 
46
. 
While CR and RKD can easily be administered in animal models of malignant tumors and there is 
anecdotal evidence and a few case reports of efficacy in humans, there has been resistance in the 
medical community to use CR for cancer patients. An alternative strategy is the unrestricted KD which 
has a long safety record for the treatment of pediatric epilepsy and may be easier for patients to maintain 
84
. Thus, this approach may meet with less resistance from the clinical community. 
In the present study, a bioluminescent mouse model of malignant glioma was used to 
demonstrate for the first time that an unrestricted KD can (1) reduce expression of the tumor hypoxia 
marker, CA IX; (2) alter the transcriptional response to hypoxia by reducing HIF-1α expression and 
decreasing activation of NF-κB; (3) reduce expression of VEGFR2 and decrease tumor microvasculature; 
(4) reduce peritumoral edema; (5) alter the expression of proteins that modify the tumor microenvironment 
during hypoxia. 
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Hypoxia is one of the fundamental biological phenomena found in a variety of solid tumors. 
Hypoxia-inducible factor-1 (HIF-1), which is controlled by rapid stabilization of the HIF1α subunit, is a 
pivotal transcriptional factor in the cellular response to hypoxia. The current study found a reduction in 
expression of HIF-1α and CA IX in tumors from animals maintained on KC. HIF-1 is a potent activator of 
angiogenesis and invasion through its upregulation of target genes critical for these functions including 
vascular endothelial growth factors (VEGF), VEGF receptors (VEGFR) and matrix metalloproteinases 
(MMP) 
85
. Carbonic anhydrase IX (CA IX) expression is also controlled by HIF-1α and is thus considered 
a marker for hypoxia. Overexpression of CA IX is common in malignant glioma and correlates with poor 
survival in patients 
86, 87
. Animals maintained on KC also showed a significant reduction in activation of 
nuclear factor kappa B (NF-κB) in their tumors, which is also a key regulator of the transcriptional 
response to hypoxia 
88
. NF-κB is linked to various signal transduction pathways and to transcriptional 
activation events that mediate inflammation, cell proliferation, cell migration, and angiogenesis 
89-91
.  
The hypothesis that tumor growth and progression can be limited by targeting angiogenesis has 
been demonstrated extensively in both preclinical and clinical studies 
92
. Vascular endothelial growth 
factor (VEGF) pathways are the main focus of anti-angiogenic therapies, which include bevacizumab, the 
monoclonal antibody targeting VEGFA 
93
. The current study demonstrated that KC altered the VEGF 
pathway at the receptor level, showing significantly reduced protein expression of VEGFR2, which is the 
main receptor responsible for modulating tumor angiogenesis 
94
. Recent studies have shown that 
selective inhibition of VEGFR2 tyrosine kinase induces a radiologic response, normalizes tumor 
vasculature, and reduces edema while increasing patient quality of life 
95-97
. Further, it has been 
suggested that a VEGFR2 blockade creates a "normalization window" where vessel structure is 
normalized and hypoxia is reduced, enhancing radiation therapy in human glioblastoma xenograft models 
98
. Total VEGF at the protein level was unaltered by the KD however gene expression analysis showed a 
significant decrease in the expression of Vegfb. Although the role of VEGFB in tumor angiogenesis is not 
well understood, it has been suggested that it may be important for angiogenic processes in a context 
dependent manner 
99-101
. Evidence suggests that decreased VEGFB expression is associated with 
improved survival and may be an indicator of response to anti-angiogenic therapies in ovarian cancer 
patients 
102, 103
. Further analysis of gene expression showed tumors in mice fed KC also had significantly 
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lower expression of plasminogen activator urokinase (Plau) and angiopoeitin-1 receptor (Tek). Both are 
thought to play a central role in tumor invasion, metastasis and angiogenesis 
104-106
. PLAU inhibitors are 
being actively explored as anticancer strategies in glioblastoma 
107-109
. Downregulation of the uPA 
pathway was shown to inhibit TEK signaling and led to a reduction in angiogenesis in glioblastoma cells 
110
. The angiogenic properties of TEK were substantiated in both a rat glioma model 
111
 and human GBM 
xenografts 
112
. TEK was also shown to be a key molecular regulator of pathological vascularization 
characteristic of malignant astrocytomas 
113
. We also found that β1 integrin (Itgb1) and tissue inhibitor of 
metalloproteinase 1 (Timp1) expression was significantly reduced when animals were maintained on KC. 
β1 integrin inhibitors are being explored as a treatment strategy for various cancers 
114-116
 and have been 
shown to potentiate antiangiogenic therapy in bevacizumab resistant glioblastoma 
117
. In addition, β1 
integrin has also been implicated in tumorigenesis, therapy resistance, invasion and metastasis 
118
. Low 
expression levels of TIMP-1 have been associated with longer survival times in GBM patients 
119, 120
. 
Recently TIMP-1 upregulation has also been shown to be involved in mechanisms of developed 
resistance to anti-VEGF treatment 
121
. 
Currently, bevacizumab is the only FDA-approved molecular drug targeting angiogenesis in GBM; 
however, this drug often results in adverse effects and only a limited improvement in survival 
122
. In 
addition, it has been shown that bevacizumab treatment can lead to increased regions of hypoxia, 
enhanced matrix metalloproteinase-2 (MMP-2) function, and a more invasive, treatment-resistant glioma 
phenotype 
123, 124
. MMPs are enzymes that remodel the extracellular matrix and alter surface protein 
expression. Increased expression and activation of MMP-2, which is linked to HIF-1α expression 
125
, can 
lead to cellular invasion 
126
 and increased BBB permeability 
127
. A study using a human xenograft model 
showed that silencing pro-MMP-2 resulted in decreased expression of VEGFR2 and enhanced 
radiosensitivity 
128
. Protein analysis of tumors from animals fed KC showed reduced expression of both 
pro- and activated-MMP-2, suggesting that KC may reduce the invasive potential of cells within the tumor. 
If metabolic therapy could be used to provide a less toxic way to limit angiogenesis it may mimic the 
beneficial effects of bevacizumab while limiting the pro-invasive selection seen with anti-angiogenic 
agents. 
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An additional reason angiogenesis presents a clinical challenge is that tumor vasculature, in 
contrast to healthy vessels, is often immature, highly permeable, structurally and functionally abnormal 
129, 
130
. This can impair delivery of therapeutic agents, alter the tumor microenvironment, drive tumor cell 
extravasation, allow for the rapid influx of inflammatory cells, and lead to peritumoral edema 
131
. A 
byproduct of this inflammation is the buildup of fluid around the tumor, or peritumoral edema, which is a 
frequent cause of morbidity and mortality in patients with gliomas. Dexamethasone is the current 
treatment of choice for peritumoral inflammation and edema, yet it comes with adverse side effects such 
as hyperglycemia, cardiovascular effects, osteoporosis, weight gain, insomnia, infection and cognitive 
effects which ultimately reduce the quality of life for patients 
132, 133
. The current study found a reduction in 
peritumoral edema in animals maintained on KC when compared to those fed SD. Leaky vasculature and 
disruption of the blood brain barrier caused by tumors is thought to occur in part because of defects in 
interendothelial tight junctions. Zona occludens-1 (ZO-1) and occludin are critical for maintaining the 
stability and functions of the tight junctions and their loss is associated with increased blood brain barrier 
permeability 
134, 135
. ZO-1 expression was significantly increased in the tumors from animals fed KC when 
compared to SD; however, there was no difference in expression of occludin. Further, both irradiation and 
hypoxic conditions have been implicated in the breakdown of the blood brain barrier (BBB) via down-
regulation of ZO-1 expression in gliomas 
136, 137
. Our results suggest that KC may help mitigate 
peritumoral edema and BBB-breakdown by preserving tight junction proteins such as ZO-1.  
Brain edema and BBB permeability are also propagated by HIF-1α expression which can 
increase expression of MMPs and aquaporin-4 (AQP4) 
138
. Several groups have proposed the 
involvement of aquaporins in the pathophysiology of brain edema 
139-141
. Aquaporins are the principle 
pathway for water movement across most cellular membranes. Of these, AQP1 and AQP4 proteins are 
found highly expressed in the most malignant gliomas 
142, 143
. The current study found a reduction in 
expression of AQP4 but not AQP1 in the tumors from animals fed a KD. In addition to its well-known 
function in brain edema, AQP4 has also been recently reported to play a role in cell migration, invasion 
and survival 
144-146
. When observed together, decreased AQP4 and MMP2 expression corresponded to 
decreased invasive ability of glioma cells 
147
.  
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CONCLUSION 
 
The anti-tumor mechanisms through which the ketogenic diet, caloric restriction (and intermittent 
fasting) and other potential metabolic therapies act are not completely understood; however, the animal 
model data strongly suggest that metabolic alteration may be a highly effective therapy as well as a 
potent adjuvant to the current standard of care for malignant brain tumors. The KD and/or CR are the only 
therapeutic approaches that simultaneously target multiple hallmarks of cancer such as energy 
metabolism, hypoxia, inflammation, angiogenesis and invasion. This suggests a number of avenues for 
further research such as: (i) Can we mimic the effects of some current chemotherapies using metabolic 
alteration; (ii) will the use of the KD provide an effective way to reduce the confounding effects of tumor 
heterogeneity by targeting the abnormal metabolic processes underlying brain tumors and many other 
cancers; and (iii) can the use of standard therapies be augmented by altering the cancer’s intrinsically 
aberrant cellular metabolism? These and other questions can only be answered using carefully 
constructed clinical trials that include metabolic alteration. Our increased understanding of metabolism as 
both a driving hallmark of cancer and an important therapeutic strategy provides important insight and 
suggest the KD may be an effective way to enhance the way brain tumors are treated. 
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